OptiNose, Inc. (OPTN) News
Filter OPTN News Items
OPTN News Results
|Loading, please wait...|
OPTN News Highlights
- For OPTN, its 30 day story count is now at 13.
- Over the past 15 days, the trend for OPTN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- EAR, NOV and SNDA are the most mentioned tickers in articles about OPTN.
Latest OPTN News From Around the Web
Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.
A Bucks County drug and delivery device developer expects to raise $50 million from a public stock offering set to close later this week. Optinose (NASDAQ: OPTN) of Yardley plans to sell 26.32 million shares of its common stock, along with warrants to purchase an equal amount of shares, at a combined price of $1.90 per share. The shares of common stock and warrants will be issued separately, but can only be purchased together in the offering, the company said.
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before dedu
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All shares of common stock and accompanying warrants to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to gra
The latest analyst coverage could presage a bad day for OptiNose, Inc. ( NASDAQ:OPTN ), with the analysts making...
OptiNose, Inc. (NASDAQ:NASDAQ:OPTN) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Peter Miller - CEO…
OptiNose ( NASDAQ:OPTN ) Third Quarter 2022 Results Key Financial Results Revenue: US$20.1m (down 8.0% from 3Q 2021...
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023
OptiNose press release (OPTN): Q3 GAAP EPS of -$0.18 in-line.Revenue of $20.1M (-7.9% Y/Y) misses by $3.3M.XHANCE Net Revenue and Average Net Revenue per Prescription: The…
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?